Overview

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

This study was designed to investigate the 1 year efficacy and safety of the 50 µg once daily (od) dose of glycopyrronium bromide (NVA237) in patients with moderate to severe chronic obstructive pulmonary disease.

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Bromides
Glycopyrrolate
Tiotropium Bromide